SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
Our studies with the prototypical NEP inhibitor SCH 34826 indicate the potential role of this class of compounds in cardiovascular modulation. The data assembled to date indicate that NEP inhibition elicits significant ANF-like effects in animals and man. The early data generated to date on SCH 34826, when considered with those data generated on other NEP inhibitors, indicate that NEP inhibition may have therapeutic utility in some forms of hypertension and congestive heart failure.
Sybertz
E J
EJ
Schering Plough Research, Bloomfield, New Jersey 07003.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor; D004148:Dioxolanes / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology*; D004357:Drug Synergism; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011355:Prodrugs; D051381:Rats
D000959:Antihypertensive Agents; D004148:Dioxolanes; D004151:Dipeptides; D011355:Prodrugs; C056319:Sch 34826; C062344:SCH 32615; D009320:Atrial Natriuretic Factor; D015260:Neprilysin